A key part of president Donald Trump’s strategy to cut drug prices was to attack global “freeloading” for pharmaceuticals, targeting countries pushing back against pharma companies trying to charge higher US-level prices for their products.
But in trade negotiations with Canada and Mexico, it looks like that the Trump administration has not followed through on the strong rhetoric set out in his drug pricing strategy published last year.
According to press reports Trump’s negotiating team have agreed to scrap provisions on exclusivity of biologics, allowing each country to decide when the patent protection period expires on biologics.
{iframe}https://pharmaphorum.com/news/pharma-fury-as-trumps-team-reneges-on-biologic-patent-rules-in-trade-talks/{/iframe}